Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day.*Conference Call Details:*
To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.
*Webcast Registration link: **https://edge.media-server.com/mmc/p/k57ufszy*
*For further information, please contact:*
*Renalytix plc * www.renalytix.com
James McCullough, CEO *Via Walbrook PR *
*Stifel (Nominated Adviser, Joint Broker)* *Tel: 020 7710 7600*
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea
*Investec Bank plc (Joint Broker)* *Tel: 020 7597 4000*
Gary Clarence / Shalin Bhamra
*Walbrook PR Limited* *Tel: 020 7933 8780 *or renalytix@walbrookpr.com
Paul McManus / Alice Woodings Mob: 07980 541 893 / 07407 804 654
*CapComm Partners*
Peter DeNardo
*Tel: 415-389-6400* or investors@renalytix.com
*About Renalytix*
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.